Adverse events in patients with LDL-C <0.65 mmol/L (<25 mg/dL) or <0.39 mmol/L (<15 mg/dL) during alirocumab treatment for up to 104 weeks: data from 14 randomized trials
Topic:
Primary cardiovascular prevention: interventions and outcomes
Speaker:
Doctor J. Robinson (Iowa, US)
Event:
ESC Congress 2016
Congress Presentation
19 more presentations in this session
Access the full session
About the event
